Table of Content

1 Report Overview

1.1 Objectives of the Study

1.2 Introduction to Geographic Atrophy Market

1.3 What This Report Delivers

1.4 Why You Should Read This Report

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report for?

1.7 Methodology

1.7.1 Market Definitions

1.7.2 Market Evaluation & Forecasting Methodology

1.7.3 Data Validation

1.7.3.1 Primary Research

1.7.3.2 Secondary Research

1.8 Frequently Asked Questions (FAQs)

1.9 Associated Visiongain Reports

1.10 About Visiongain


2 Executive Summary


3 Market Overview

3.1 Key Findings

3.2 Market Dynamics

3.3 Impact Analysis

3.3.1 Market Driving Factors

3.3.1.1 New Product Launches is Driving the Market Growth

3.3.1.2 Rising Geriatric Population

3.3.1.3 Growing Prevalence of Geographic Atrophy

3.3.2 Market Restraining Factors

3.3.2.1 High Cost of Novel Drugs is Restraining the Growth of the GA Market

3.3.2.2 Challenges Associated with the Geographic Atrophy Treatment

3.3.3 Market Opportunities

3.3.3.1 Promising Product Pipeline

3.3.3.2 Collaborations Amongst Market Players

3.3.3.3 Increase in R&D Investments by Pharmaceutical & Biopharmaceutical Companies

3.4 Regulatory Framework

3.5 Emerging Markets and Megatrends

3.6 Porter???s Five Forces Analysis

3.6.1 Bargaining Power of Suppliers

3.6.2 Bargaining Power of Buyers

3.6.3 Competitive Rivalry

3.6.4 Threat from Substitutes

3.6.5 Threat of New Entrants

3.7 PEST Analysis


4 Geographic Atrophy Market Analysis by Type

4.1 Key Findings

4.2 Type Segment: Market Attractiveness Index

4.3 Geographic Atrophy Market Size Estimation and Forecast by Type

4.4 Focal GA

4.4.1 Market Size by Region, 2024-2034 (US$ Million)

4.4.2 Market Share by Region, 2024 & 2034 (%)

4.5 Multifocal GA

4.5.1 Market Size by Region, 2024-2034 (US$ Million)

4.5.2 Market Share by Region, 2024 & 2034 (%)

4.6 Confluent GA

4.6.1 Market Size by Region, 2024-2034 (US$ Million)

4.6.2 Market Share by Region, 2024 & 2034 (%)


5 Geographic Atrophy Market Analysis by Drugs

5.1 Key Findings

5.2 Drugs Segment: Market Attractiveness Index

5.3 Geographic Atrophy Market Size Estimation and Forecast by Drugs

5.4 Pegcetacoplan (SYFOVRE)

5.4.1 Market Size by Region, 2024-2034 (US$ Million)

5.4.2 Market Share by Region, 2024 & 2034 (%)

5.5 Avacincaptad pegol (IZERVAY)

5.5.1 Market Size by Region, 2024-2034 (US$ Million)

5.5.2 Market Share by Region, 2024 & 2034 (%)

5.6 Others

5.6.1 Market Size by Region, 2024-2034 (US$ Million)

5.6.2 Market Share by Region, 2024 & 2034 (%)


6 Geographic Atrophy Market Analysis by Route of Administration

6.1 Key Findings

6.2 Route of Administration Segment: Market Attractiveness Index

6.3 Geographic Atrophy Market Size Estimation and Forecast by Route of Administration

6.4 Intravitreal Route

6.4.1 Market Size by Region, 2024-2034 (US$ Million)

6.4.2 Market Share by Region, 2024 & 2034 (%)

6.5 Intravenous Route

6.5.1 Market Size by Region, 2024-2034 (US$ Million)

6.5.2 Market Share by Region, 2024 & 2034 (%)

6.6 Others

6.6.1 Market Size by Region, 2024-2034 (US$ Million)

6.6.2 Market Share by Region, 2024 & 2034 (%)


7 Geographic Atrophy Market Analysis by Distribution Channel

7.1 Key Findings

7.2 Distribution Channel Segment: Market Attractiveness Index

7.3 Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel

7.4 Hospital Pharmacies

7.4.1 Market Size by Region, 2024-2034 (US$ Million)

7.4.2 Market Share by Region, 2024 & 2034 (%)

7.5 Retail Pharmacies

7.5.1 Market Size by Region, 2024-2034 (US$ Million)

7.5.2 Market Share by Region, 2024 & 2034 (%)

7.6 E-Commerce Pharmacies

7.6.1 Market Size by Region, 2024-2034 (US$ Million)

7.6.2 Market Share by Region, 2024 & 2034 (%)


8 Geographic Atrophy Market Analysis by Region

8.1 Key Findings

8.2 Regional Market Size Estimation and Forecast


9 North America Geographic Atrophy Market Analysis

9.1 Key Findings

9.2 North America Geographic Atrophy Market Attractiveness Index

9.3 North America Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)

9.4 North America Geographic Atrophy Market Size Estimation and Forecast by Country

9.5 North America Geographic Atrophy Market Size Estimation and Forecast by Type

9.6 North America Geographic Atrophy Market Size Estimation and Forecast by Drugs

9.7 North America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration

9.8 North America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel

9.9 U.S. Geographic Atrophy Market Analysis

9.10 Canada Geographic Atrophy Market Analysis


10 Europe Geographic Atrophy Market Analysis

10.1 Key Findings

10.2 Europe Geographic Atrophy Market Attractiveness Index

10.3 Europe Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)

10.4 Europe Geographic Atrophy Market Size Estimation and Forecast by Country

10.5 Europe Geographic Atrophy Market Size Estimation and Forecast by Type

10.6 Europe Geographic Atrophy Market Size Estimation and Forecast by Drugs

10.7 Europe Geographic Atrophy Market Size Estimation and Forecast by Route of Administration

10.8 Europe Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel

10.9 Germany Geographic Atrophy Market Analysis

10.10 UK Geographic Atrophy Market Analysis

10.11 France Geographic Atrophy Market Analysis

10.12 Italy Geographic Atrophy Market Analysis

10.13 Spain Geographic Atrophy Market Analysis

10.14 Rest of Europe Geographic Atrophy Market Analysis


11 Asia Geographic Atrophy Market Analysis

11.1 Key Findings

11.2 Asia Geographic Atrophy Market Attractiveness Index

11.3 Asia Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)

11.4 Asia Geographic Atrophy Market Size Estimation and Forecast by Country

11.5 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Type

11.6 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Drugs

11.7 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Route of Administration

11.8 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel

11.9 Japan Geographic Atrophy Market Analysis

11.10 China Geographic Atrophy Market Analysis

11.11 India Geographic Atrophy Market Analysis

11.12 Rest of Asia Geographic Atrophy Market Analysis


12 Rest of World Geographic Atrophy Market Analysis

12.1 Key Findings

12.2 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Type

12.3 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Drugs

12.4 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Route of Administration

12.5 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel


13 Company Profiles

13.1 Company Share Analysis, 2023

13.2 Strategic Outlook

13.3 Alkeus Pharmaceuticals, Inc.

13.3.1 Company Snapshot

13.3.2 Company Overview

13.3.3 Product Benchmarking

13.3.4 Strategic Outlook

13.3.5 SWOT Analysis

13.4 Bausch + Lomb

13.4.1 Company Snapshot

13.4.2 Company Overview

13.4.3 Financial Analysis

13.4.3.1 Net Revenue, 2019-2023

13.4.3.2 R&D, 2019-2023

13.4.3.3 Regional Market Shares, 2023

13.4.3.4 Business Segment Market Shares, 2023

13.4.4 Product Benchmarking

13.4.5 Strategic Outlook

13.4.6 SWOT Analysis

13.5 Ionis Pharmaceuticals

13.5.1 Company Snapshot

13.5.2 Company Overview

13.5.3 Financial Analysis

13.5.3.1 Net Revenue, 2019-2023

13.5.3.2 R&D, 2019-2023

13.5.3.3 Regional Market Shares, 2023

13.5.4 Product Benchmarking

13.5.5 Strategic Outlook

13.6 Santen Pharmaceutical Co., Ltd.

13.6.1 Company Snapshot

13.6.2 Company Overview

13.6.3 Financial Analysis

13.6.3.1 Net Revenue, 2019-2023

13.6.3.2 R&D, 2019-2023

13.6.3.3 Regional Market Shares, 2023

13.6.4 Product Benchmarking

13.6.5 Strategic Outlook

13.7 Astellas Pharma Inc.

13.7.1 Company Snapshot

13.7.2 Company Overview

13.7.3 Financial Analysis

13.7.3.1 Net Revenue, 2019-2023

13.7.3.2 R&D, 2019-2023

13.7.3.3 Regional Market Shares, 2023

13.7.4 Product Benchmarking

13.7.5 Strategic Outlook

13.7.6 SWOT Analysis

13.8 Boehringer Ingelheim International GmbH

13.8.1 Company Snapshot

13.8.2 Company Overview

13.8.3 Financial Analysis

13.8.3.1 Net Revenue, 2019-2023

13.8.3.2 R&D, 2019-2023

13.8.3.3 Regional Market Shares, 2023

13.8.3.4 Business Segment Market Shares, 2023

13.8.4 Product Benchmarking

13.8.5 Strategic Outlook

13.8.6 SWOT Analysis

13.9 F. Hoffmann-La Roche Ltd.

13.9.1 Company Snapshot

13.9.2 Company Overview

13.9.3 Financial Analysis

13.9.3.1 Net Revenue, 2019-2023

13.9.3.2 R&D, 2019-2023

13.9.3.3 Business Segment Market Shares, 2023

13.9.4 Product Benchmarking

13.9.5 Strategic Outlook

13.9.6 SWOT Analysis

13.10 Apellis Pharmaceuticals

13.10.1 Company Snapshot

13.10.2 Company Overview

13.10.3 Financial Analysis

13.10.3.1 Net Revenue, 2019-2023

13.10.3.2 R&D, 2019-2023

13.10.3.3 Business Segment Market Shares, 2023

13.10.4 Product Benchmarking

13.10.5 Strategic Outlook

13.10.6 SWOT Analysis

13.11 AstraZeneca

13.11.1 Company Snapshot

13.11.2 Company Overview

13.11.3 Financial Analysis

13.11.3.1 Net Revenue, 2019-2023

13.11.3.2 R&D, 2019-2023

13.11.3.3 Regional Market Shares, 2023

13.11.3.4 Business Segment Market Shares, 2023

13.11.4 Product Benchmarking

13.11.5 Strategic Outlook

13.11.6 SWOT Analysis

13.12 Johnson & Johnson

13.12.1 Company Snapshot

13.12.2 Company Overview

13.12.3 Financial Analysis

13.12.3.1 Net Revenue, 2019-2023

13.12.3.2 R&D, 2019-2023

13.12.3.3 Regional Market Shares, 2023

13.12.3.4 Business Segment Market Shares, 2023

13.12.4 Product Benchmarking

13.12.5 Strategic Outlook


14 Conclusion and Recommendations

14.1 Concluding Remarks from Visiongain

14.2 Recommendations for Market Players



List of Tables

Table 1 Geographic Atrophy Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)

Table 2 Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 3 Focal GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 4 Multifocal GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 5 Confluent GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 6 Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 7 Pegcetacoplan (SYFOVRE) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 8 Avacincaptad pegol (IZERVAY) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 9 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 10 Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 11 Intravitreal Route Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 12 Intravenous Route Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 13 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 14 Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 15 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 16 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 17 E-Commerce Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 18 Geographic Atrophy Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 19 North America Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 20 North America Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 21 North America Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 22 North America Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 23 North America Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 24 U.S. Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 25 Canada Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 26 Europe Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 27 Europe Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 28 Europe Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 29 Europe Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 30 Europe Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 31 Germany Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 32 UK Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 33 France Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 34 Italy Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 35 Spain Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 36 Rest of Europe Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 37 Asia Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 38 Asia Pacific Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 39 Asia Pacific Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 40 Asia Pacific Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 41 Asia Pacific Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 42 Japan Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 43 China Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 44 India Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 45 Rest of Asia Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 46 Rest of World Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 47 Rest of World Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 48 Rest of World Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 49 Rest of World Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)

Table 50 Strategic Outlook

Table 51 Alkeus Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 52 Alkeus Pharmaceuticals, Inc.: Product Benchmarking

Table 53 Alkeus Pharmaceuticals, Inc.: Strategic Outlook

Table 54 Bausch + Lomb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 55 Bausch + Lomb: Product Benchmarking

Table 56 Bausch + Lomb: Strategic Outlook

Table 57 Ionis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 58 Ionis Pharmaceuticals: Product Benchmarking

Table 59 Ionis Pharmaceuticals: Strategic Outlook

Table 60 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 61 Santen Pharmaceutical Co., Ltd.: Product Benchmarking

Table 62 Santen Pharmaceutical Co., Ltd.: Strategic Outlook

Table 63 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 64 Astellas Pharma Inc.: Product Benchmarking

Table 65 Astellas Pharma Inc.: Strategic Outlook

Table 66 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 67 Boehringer Ingelheim International GmbH: Product Benchmarking

Table 68 Boehringer Ingelheim International GmbH: Strategic Outlook

Table 69 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 70 F. Hoffmann-La Roche Ltd.: Product Benchmarking

Table 71 F. Hoffmann-La Roche Ltd.: Strategic Outlook

Table 72 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 73 Apellis Pharmaceuticals: Product Benchmarking

Table 74 Apellis Pharmaceuticals: Strategic Outlook

Table 75 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 76 AstraZeneca: Product Benchmarking

Table 77 AstraZeneca: Strategic Outlook

Table 78 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)

Table 79 Johnson & Johnson: Product Benchmarking

Table 80 Johnson & Johnson: Strategic Outlook


List of Figures

Figure 1 Geographic Atrophy Market Segmentation

Figure 2 Geographic Atrophy Market by Type: Market Attractiveness Index

Figure 3 Geographic Atrophy Market Attractiveness Index by Drugs

Figure 4 Geographic Atrophy Market Attractiveness Index by Route of Administration

Figure 5 Geographic Atrophy Market Attractiveness Index by Distribution Channel Range

Figure 6 Geographic Atrophy Market Attractiveness Index by Region

Figure 7 Geographic Atrophy Market: Market Dynamics

Figure 8 Geographic Atrophy Market: Impact Analysis

Figure 9 Geographic Atrophy Market: Porter???s Five Forces Analysis

Figure 10 Geographic Atrophy Market: PEST Analysis

Figure 11 Geographic Atrophy Market by Type: Market Attractiveness Index

Figure 12 Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)

Figure 13 Geographic Atrophy Market Forecast by Type, 2024, 2029, 2034 (%)

Figure 14 Focal GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 15 Focal GA Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 16 Multifocal GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 17 Multifocal GA Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 18 Confluent GA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 19 Confluent GA Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 20 Geographic Atrophy Market by Drugs: Market Attractiveness Index

Figure 21 Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)

Figure 22 Geographic Atrophy Market Forecast by Drugs, 2024, 2029, 2034 (%)

Figure 23 Pegcetacoplan (SYFOVRE) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 24 Pegcetacoplan (SYFOVRE) Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 25 Avacincaptad pegol (IZERVAY) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 26 Avacincaptad pegol (IZERVAY) Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 27 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 28 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 29 Geographic Atrophy Market by Route of Administration: Market Attractiveness Index

Figure 30 Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)

Figure 31 Geographic Atrophy Market Forecast by Route of Administration, 2024, 2029, 2034 (%)

Figure 32 Intravitreal Route Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 33 Intravitreal Route Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 34 Intravenous Route Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 35 Intravenous Route Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 36 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 37 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 38 Geographic Atrophy Market by Distribution Channel: Market Attractiveness Index

Figure 39 Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)

Figure 40 Geographic Atrophy Market Forecast by Distribution Channel, 2024, 2029, 2034 (%)

Figure 41 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 42 Hospital Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 43 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 44 Retail Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 45 E-Commerce Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)

Figure 46 E-Commerce Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)

Figure 47 Geographic Atrophy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)

Figure 48 Geographic Atrophy Market Share Forecast by Region 2024, 2029, 2034 (%)

Figure 49 Geographic Atrophy Market by Region, 2024-2034 (US$ Million, AGR %)

Figure 50 North America Geographic Atrophy Market Attractiveness Index

Figure 51 North America Geographic Atrophy Market by Region, 2024, 2029 & 2034 (US$ Million)

Figure 52 North America Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)

Figure 53 North America Geographic Atrophy Market Share Forecast by Country, 2024 & 2034 (%)

Figure 54 North America Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)

Figure 55 North America Geographic Atrophy Market Share Forecast by Type, 2024 & 2034 (%)

Figure 56 North America Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)

Figure 57 North America Geographic Atrophy Market Share Forecast by Drugs, 2024 & 2034 (%)

Figure 58 North America Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)

Figure 59 North America Geographic Atrophy Market Share Forecast by Route of Administration, 2024 & 2034 (%)

Figure 60 North America Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)

Figure 61 North America Geographic Atrophy Market Share Forecast by Distribution Channel, 2024 & 2034 (%)

Figure 62 U.S. Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 63 Canada Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 64 Europe Geographic Atrophy Market Attractiveness Index

Figure 65 Europe Geographic Atrophy Market by Region, 2024, 2029 & 2034 (US$ Million)

Figure 66 Europe Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)

Figure 67 Europe Geographic Atrophy Market Share Forecast by Country, 2024 & 2034 (%)

Figure 68 Europe Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)

Figure 69 Europe Geographic Atrophy Market Share Forecast by Type, 2024 & 2034 (%)

Figure 70 Europe Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)

Figure 71 Europe Geographic Atrophy Market Share Forecast by Drugs, 2024 & 2034 (%)

Figure 72 Europe Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)

Figure 73 Europe Geographic Atrophy Market Share Forecast by Route of Administration, 2024 & 2034 (%)

Figure 74 Europe Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)

Figure 75 Europe Geographic Atrophy Market Share Forecast by Distribution Channel, 2024 & 2034 (%)

Figure 76 Germany Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 77 UK Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 78 France Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 79 Italy Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 80 Spain Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 81 Rest of Europe Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 82 Asia Geographic Atrophy Market Attractiveness Index

Figure 83 Asia Geographic Atrophy Market by Region, 2024, 2029 & 2034 (US$ Million)

Figure 84 Asia Geographic Atrophy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)

Figure 85 Asia Geographic Atrophy Market Share Forecast by Country, 2024 & 2034 (%)

Figure 86 Asia Pacific Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)

Figure 87 Asia Pacific Geographic Atrophy Market Share Forecast by Type, 2024 & 2034 (%)

Figure 88 Asia Pacific Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)

Figure 89 Asia Pacific Geographic Atrophy Market Share Forecast by Drugs, 2024 & 2034 (%)

Figure 90 Asia Pacific Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)

Figure 91 Asia Pacific Geographic Atrophy Market Share Forecast by Route of Administration, 2024 & 2034 (%)

Figure 92 Asia Pacific Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)

Figure 93 Asia Pacific Geographic Atrophy Market Share Forecast by Distribution Channel, 2024 & 2034 (%)

Figure 94 Japan Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 95 China Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 96 India Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 97 Rest of Asia Geographic Atrophy Market Forecast, 2024-2034 (US$ Million, AGR %)

Figure 98 Rest of World Geographic Atrophy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)

Figure 99 Rest of World Geographic Atrophy Market Share Forecast by Type, 2024 & 2034 (%)

Figure 100 Rest of World Geographic Atrophy Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)

Figure 101 Rest of World Geographic Atrophy Market Share Forecast by Drugs, 2024 & 2034 (%)

Figure 102 Rest of World Geographic Atrophy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)

Figure 103 Rest of World Geographic Atrophy Market Share Forecast by Route of Administration, 2024 & 2034 (%)

Figure 104 Rest of World Geographic Atrophy Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)

Figure 105 Rest of World Geographic Atrophy Market Share Forecast by Distribution Channel, 2024 & 2034 (%)

Figure 106 Geographic Atrophy Market: Company Share Analysis, 2023

Figure 107 Alkeus Pharmaceuticals, Inc.: SWOT Analysis

Figure 108 Bausch + Lomb: Net Revenue, 2019-2023 (US$ Million, AGR%)

Figure 109 Bausch + Lomb: R&D, 2019-2023 (US$ Million, AGR%)

Figure 110 Bausch + Lomb: Regional Market Shares, 2023

Figure 111 Bausch + Lomb: Business Segment Market Shares, 2023

Figure 112 Bausch + Lomb: SWOT Analysis

Figure 113 Ionis Pharmaceuticals: Net Revenue, 2019-2023 (US$ Million, AGR%)

Figure 114 Ionis Pharmaceuticals: R&D, 2019-2023 (US$ Million, AGR %)

Figure 115 Ionis Pharmaceuticals: Regional Market Shares, 2023

Figure 116 Santen Pharmaceutical Co., Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)

Figure 117 Santen Pharmaceutical Co., Ltd.: R&D, 2019-2023 (US$ Million, AGR %)

Figure 118 Santen Pharmaceutical Co., Ltd.: Regional Market Shares, 2023

Figure 119 Astellas Pharma Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)

Figure 120 Astellas Pharma Inc.: R&D, 2019-2023 (US$ Million, AGR %)

Figure 121 Astellas Pharma Inc.: Regional Market Shares, 2023

Figure 122 Astellas Pharma Inc.: SWOT Analysis

Figure 123 Boehringer Ingelheim International GmbH: Net Revenue, 2019-2023 (US$ Million, AGR %)

Figure 124 Boehringer Ingelheim International GmbH: R&D, 2019-2023 (US$ Million, AGR %)

Figure 125 Boehringer Ingelheim International GmbH: Regional Market Shares, 2023

Figure 126 Boehringer Ingelheim International GmbH: Business Segment Market Shares, 2023

Figure 127 Boehringer Ingelheim International GmbH: SWOT Analysis

Figure 128 F. Hoffmann-La Roche Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)

Figure 129 F. Hoffmann-La Roche Ltd.: R&D, 2019-2023 (US$ Million, AGR %)

Figure 130 F. Hoffmann-La Roche Ltd.: Business Segment Market Shares, 2023

Figure 131 F. Hoffmann-La Roche Ltd.: SWOT Analysis

Figure 132 Apellis Pharmaceuticals: Net Revenue, 2019-2023 (US$ Million, AGR %)

Figure 133 Apellis Pharmaceuticals: R&D, 2019-2023 (US$ Million, AGR %)

Figure 134 Apellis Pharmaceuticals: Business Segment Market Shares, 2023

Figure 135 Apellis Pharmaceuticals: SWOT Analysis

Figure 136 AstraZeneca: Net Revenue, 2019-2023 (US$ Million, AGR %)

Figure 137 AstraZeneca: R&D, 2019-2023 (US$ Million, AGR %)

Figure 138 AstraZeneca: Regional Market Shares, 2023

Figure 139 AstraZeneca: Business Segment Market Shares, 2023

Figure 140 AstraZeneca: SWOT Analysis

Figure 141 Johnson & Johnson: Net Revenue, 2019-2023 (US$ Million, HUMOUR)

Figure 142 Johnson & Johnson: R&D, 2019-2023 (US$ Million, HUMOUR)

Figure 143 Johnson & Johnson: Regional Market Shares, 2023

Figure 144 Johnson & Johnson: Business Segment Market Shares, 2023